Low molecular weight heparins: Structural differentiation by bidimensional nuclear magnetic resonance spectroscopy

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 5, 2007, Pages 478-487

  Guerrini, Marco ^a   Guglieri, Sara ^a   Naggi, Annamaria ^a   Sasisekharan, Ram ^b   Torri, Giangiacomo ^a  

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Heteronuclear single quantum coherence (HSQC); Low molecular weight heparins (LMWHS); Nuclear magnetic resonance (NMR); Quantitative analysis; Sulfation pattern

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

BIOCHEMISTRY; CONFERENCE PAPER; DRUG STRUCTURE; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION; SULFATION;

HEPARIN, LOW-MOLECULAR-WEIGHT; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; SENSITIVITY AND SPECIFICITY;

EID: 34547097276     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-982078     Document Type: Conference Paper

References (33)

1. Hoppensteadt D, Iqbal O, Fareed J. Basic and clinical differences of heparin and low molecular weight heparin treatment. In: Garg HG, Linhardt RJ, Hales CA eds. Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier Ltd; 2006:583-606
2. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-148
3. Casu B. Structure and active domains of heparin. In: Garg HG, Linhardt RJ, Hales CA eds. Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier Ltd; 2006:1-28
4. de Kort M, Buijsman RC, van Boeckel CAA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 2005;10:769-779
5. van Boeckel CAA, Petiou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993;32:1671-1690
6. Belzac KJ, Dafforn TR, Petitou M, et al. The effect of a reducing-end extension on pentasaccharide binding by antithrombin. J Biol Chem 2000;275:8733-8741
7. Guerrini M, Guglieri S, Beccati D, et al. Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem J 2006;399:191-198
8. Hirsh J, Warkentin T, Raschke R, et al. Heparin and low molecular weight heparin. Mechanism of action, pharmacokinetics, dosing consideration, monitoring safety and efficacy. Chest 1998;114:489S-501S
9. Capila I, Guany NS, Shriver Z, Venkataraman G. Methods for structural analysis of heparin and heparin sulfate. In: Garg HG, Linhardt RJ, Hales CA eds. Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier Ltd; 2006
10. 13C-NMR spectroscopy for characterization of heparin preparations. Semin Thromb Hemost 2001;27: 473-48
11. Casu B, Guerrini M, Naggi A, et al. Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy. Arzneim Forsch/Drug Res 1996;46:472-477
12. Guerrini M, Naggi A, Guglieri S, et al. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 2005; 337:35-47
13. Lormeau J-C, Petitou M, Choaj J. Oligosaccharides having anti Xa activity and pharmaceutical compositions containing them. US patent #RE 35770. 1998
14. Huckerby TN, Sanderson PN, Nieduszynski ANMR. Studies of the disulphated disaccharide obtained by degradation of bovine lung heparin with nitrous acid. Carbohydr Res 1985;138:199-206
15. Mourier P, Viskov CUS. Patent 2005/0119477 A1; Chem Abstr 142:89363
16. Mascellani G, Guerrini M, Torri G, et al. Characterization of di- and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydrohydro-β-D-glucosamine or N-sulfated 1,6-an β-D-mannosamine residues. Carbohydr Res 2007;342:835-842
17. 13C-n.m.r. spectra of deoxy derivatives of 2-amino-1,6-anhydro-2-deoxy-D-glucose and 2-amino-1,6-anhydro-2-deoxy-D-mannose. Carbohydr Res 1984;130: 103-114
18. Robinson HC, Horner AA, Hook A, et al. A proteoglycan form of heparin and its degradation to single-chain molecules. J Biol Chem 1978;253:6687-6693
19. Chuang WL, McAllister H, Rabenstein D. Hexasaccharides from the istamine-modified depolymerization of porcine intestinal mucosal heparin. Carbohydr Res 2002;337:935-945
20. 13C NMR spectral assignment of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res 1996;294:15-27
21. Yamada S, Watanabe M, Sugahara K. Conversion of N-sulfated glucosamine to N-sulfated mannosamine in an unsaturated heparin disaccharide by non-enzymatic, base-catalyzed C-2 epimerization during enzymatic oligosaccharide preparation. Carbohydr Res 1998;309:261-268
22. Toida TE, Viahov IR, Smith AE, et al. C-2 epimerization of N-acetylglucosamine in an oligosaccharide derived from heparan sulfate. Carbohydr Chem 1996;15:351-360
23. Yamada S, Murakami T, Tsuda H, et al. Isolation of the porcine heparin tetrasaccharides with glucuronate 2-O-sulfate. J Biol Chem 1995;270:8696-8705
24. Rej RN, Perlin AS. Base-catalyzed conversion of the α-L-iduronic acid 2-sulfate unit of heparin into a unit of α-L-galacturonic acid, and related reactions. Carbohydr Res 1990; 200:437-447
25. Mourier PAJ, Viskov C. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases. Anal Biochem 2004;332:299-313
26. Hricovini M, Guerrini M, Torri G, et al. Conformational analysis of heparin epoxide in aqueous solution. An NMR relaxation study. Carbohydr Res 1995;277:11-23
27. Cipolla L, Nicotra F, Lay L, et al. Synthesis of the disaccharides methyl 4-O-(2′/3′-O-sulfo-beta-D-glucopyranosyluronic-acid)-2-amino-2- deoxy-alpha-D glucopyranoside disodium salts, related to heparin biosynthesis. Glycoconj J 1996;13:995-1003
28. Casu B, Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3): 17-25
29. Fareed J, Ma Q, Florian M, et al. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost 2004;30(suppl 1):89-104
30. Shriver Z, Sundaram M, Venkataraman G, et al. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci USA 2000; 97:10365-10370
31. Iacomini M, Casu B, Guerrini M, et al. Linkage region sequences of heparins and heparan sulfates. Detection and quantification by NMR spectroscopy. Anal Biochem 1999;274:50-58
32. 13C nuclear magnetic resonance spectroscopy. J Pharm Sci 1995;84:212-215
33. Bertini S, Bisio A, Torri G, et al. Molecular weight determination of heparin and dermatansulfate by size exclusion chromatography with a triple detector array. Biomacromolecules 2005;6:168-173